The latest financial statement is for the quarter ending 2026-03-31.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 |
|---|---|---|---|
| Net loss | -4,576 | -6,158 | -154,258 |
| Stock-based compensation | 1,484 | 2,032 | 140,403 |
| Prepaid expenses | 540 | 576 | 10 |
| Other assets | - | 0 | -9,851 |
| Accounts payable | 511 | 1,624 | 521 |
| Accrued expenses | 451 | -527 | 1,231 |
| Net cash used in operating activities | -2,670 | -3,605 | -2,262 |
| Proceeds from business combination | - | 1 | 26 |
| Proceeds from related party loans | 3,503 | -4,063 | 9,911 |
| Repayment of promissory notes | 750 | - | - |
| Payments of deferred offering costs | -7,602 | - | 7,602 |
| Net cash provided by financing activities | 2,753 | 3,540 | 2,335 |
| Net change in cash and cash equivalents | 83 | -65 | 73 |
| Cash and cash equivalents at beginning of period | 20 | 85 | 12 |
| Cash and cash equivalents at end of period | 103 | 20 | 85 |
Semnur Pharmaceuticals, Inc. (SMNRW)
Semnur Pharmaceuticals, Inc. (SMNRW)